2. Signaling Pathways
  3. Antibody-drug Conjugate/ADC Related
  4. Drug-Linker Conjugates for ADC

Drug-Linker Conjugates for ADC

ADC-Related Custom Services

Drug-Linker Conjugates for ADC

Related Products

PDF 0.45 MB

Drug-Linker Conjugates for Antibody Drug Conjugates (ADCs) comprise of an active cytotoxic drug and an appropriate linker. After linked to a monoclonal antibody, those conjugates can be used for making ADCs, which are targeted agents for cancer cells with high selectivity and cytotoxicity.

The drug units in drug-linker conjugates are cytotoxic agents (i.e. ADC cytotoxins or payloads) with antitumor activity and can be classified in DNA damaging agents and tubulin inhibitors. The most commonly used DNA damaging agents in ADCs are Duocarmycins, Pyrrolobenzodiazepines, Camptothecins and Daunorubicins/Doxorubicins, while the popular tubulin inhibitors are Auristatins and Maytansinoids. Besides, there are also many traditional cytotoxic agents can be used in ADCs.

ADC linkers currently undergoing clinical evaluation are mostly classified into two categories: cleavable and noncleavable. Cleavable linkers rely on processes inside the cell to liberate the toxin, and noncleavable linkers require proteolytic degradation of the antibody portion of the ADC for release of the cytotoxic molecule.

Drug-Linker Conjugates for ADC Isoform Specific Products:

Drug-Linker Conjugates for ADC Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-164788
    GGFG-PAB-MMAE
    		99.27%
    GGFG-PAB-MMAE (Comp 58054-1) is a drug-linker conjugate for ADC. GGFG-PAB-MMAE contains the ADC linker (GGFG-PAB) and a potent tubulin polymerization inhibitor MMAE (HY-15162).
    GGFG-PAB-MMAE
  • HY-139018A
    TLR7/8 agonist 4 hydroxy-PEG10-acid hydrochloride
    TLR7/8 agonist 4 hydroxy-PEG10-acid hydrochloride (compound 9) is a drug-linker conjugates for ADC with potent antitumor activity by using TLR7/8 agonist 4 (HY-139018; a TLR7/8 agonist), linked via the non-cleavable ADC linker hydroxy-PEG10-acid (HY-133307).
    TLR7/8 agonist 4 hydroxy-PEG10-acid hydrochloride
  • HY-160649
    MC-Gly-Gly-Phe-Gly-GABA-Exatecan
    		99.72%
    MC-Gly-Gly-Phe-Gly-GABA-Exatecan is an agent linker conjugate for ADC, with an inhibitor for Topoisomerase Exatecan (HY-13631) with IC50 of 22 μM. MC-Gly-Gly-Phe-Gly-GABA-Exatecan targets various antibodies, exhibits cytotoxic and antitumor efficacy in vitro and in vivo.
    MC-Gly-Gly-Phe-Gly-GABA-Exatecan
  • HY-19697
    Aminocaproyl-Val-Cit-PABC-MMAE
    		99.89%
    Aminocaproyl-Val-Cit-PABC-MMAE is an Drug-linker conjugate for ADC.
    Aminocaproyl-Val-Cit-PABC-MMAE
  • HY-148339
    Fmoc-VAP-MMAE
    Fmoc-VAP-MMAE is a agent-linker conjugates for ADC. Fmoc-VAP-MMAE consists of an ADC linker and a tubulin inhibitor MMAE (HY-15162), with a protective Fmoc group.
    Fmoc-VAP-MMAE
  • HY-152121
    Glucocorticoid receptor agonist-1 phosphate Ala-Ala-Mal
    Glucocorticoid receptor agonist-1 phosphate Ala-Ala-Mal is a glucocorticoid receptor agonist. Glucocorticoid receptor agonist-1 phosphate Ala-Ala-Mal can be used in anti-CD40 antibody agent conjugate (ADC). Glucocorticoid receptor agonist-1 phosphate Ala-Ala-Mal can be used for the research of inflammation and immune regulation.
    Glucocorticoid receptor agonist-1 phosphate Ala-Ala-Mal
  • HY-157284
    Cys-mc-MMAE
    		99.85%
    Cys-mc-MMAE is a Drug-Linker Conjugates for ADC, and consists of Monomethyl auristatin E (HY-15162) and a linker. Cys-mc-MMAE can be used for synthesis of ADCs.
    Cys-mc-MMAE
  • HY-156691A
    TLR7/8 agonist 4 hydroxy-PEG6-acid hydrochloride
    TLR7/8 agonist 4 hydroxy-PEG6-acid hydrochloride is a drug-linker conjugates for ADC>. TLR7/8 agonist 4 hydroxy-PEG6-acid hydrochloride is the hydrochloride form of TLR7/8 agonist 4 hydroxy-PEG6-acid. TLR7/8 agonist 4 hydroxy-PEG6-acid consists of TLR7/8 agonist 4 (HY-139017) and a non-cleavable linker Hydroxy-PEG6-acid (HY-133050), and can be used for synthesis of ADCs.
    TLR7/8 agonist 4 hydroxy-PEG6-acid hydrochloride
  • HY-13631O
    (1R)-Deruxtecan
    (1R)-Deruxtecan is a drug-linker conjugates for ADC.
    (1R)-Deruxtecan
  • HY-15740
    Mc-MMAD
    		98.50%
    Mc-MMAD is a protective group (maleimidocaproyl)-conjugated MMAD. MMAD is a potent tubulin inhibitor. Mc-MMAD is a agent-linker conjugate for ADC.
    Mc-MMAD
  • HY-160899A
    Thailanstatin A cyclohexane diamine formic
    Thailanstatin A cyclohexane diamine formic is an analog of Spliceostatin (HY-16466). Thailanstatin A cyclohexane diamine formic inhibits proliferations of cells N87 (IC50 is 0.33 μM), BT474 (IC50 is 0.34 μM), MDA-MB-361-DYT2 (IC50 is 0.88 μM) and MDA-MB-468 (IC50 is 0.27 μM). Thailanstatin A cyclohexane diamine formic is used as a drug-linker conjugate for ADC molecule.
    Thailanstatin A cyclohexane diamine formic
  • HY-W190927
    MC-Val-Cit-Doxorubicin
    MC-Val-Cit-Doxorubicin is drug-linker conjugate for ADC. The maleimide can conjugate with thiol containing molecules. Doxorubicin is an anthracycline antibiotic with antineoplastic activity
    MC-Val-Cit-Doxorubicin
  • HY-153031A
    Val-Cit-PAB-Exatecan TFA
    		99.73%
    Val-Cit-PAB-Exatecan (Val-Cit-PAB-DX8951) TFA is a agent-linker conjugate for ADC. Val-Cit-PAB-Exatecan TFA is composed of a DNA topoisomerase I DX-8951 (HY-13631) and a cathepsin cleavable ADC linker.
    Val-Cit-PAB-Exatecan TFA
  • HY-15750
    Cys-mcMMAD
    		98.77%
    Cys-mcMMAD is a agent-linker conjugate for ADC. MMAD is a potent tubulin inhibitor.
    Cys-mcMMAD
  • HY-128909
    MC-Val-Cit-PAB-rifabutin
    MC-Val-Cit-PAB-rifabutin is a agent-linker conjugate for ADC with potent antitumor activity by using rifabutin (an DNA-dependent RNA polymerase inhibitor), linked via the ADC linker MC-Val-Cit-PAB.
    MC-Val-Cit-PAB-rifabutin
  • HY-128906
    MC-Val-Cit-PAB-Retapamulin
    		99.00%
    MC-Val-Cit-PAB-Retapamulin is a agent-linker conjugate for ADC with potent antitumor activity by using Retapamulin (a ribosome inhibitor), linked via the ADC linker MC-Val-Cit-PAB.
    MC-Val-Cit-PAB-Retapamulin
  • HY-148194
    SC239
    		99.97%
    SC239 is a cleavable 2-aminophenyl hemiasterlin agent-linker. SC239 can be as the agent-linker for ADC. SC239 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
    SC239
  • HY-128908
    MC-Val-Cit-PAB-Indibulin
    MC-Val-Cit-PAB-Indibulin is a agent-linker conjugate for ADC with potent antitumor activity by using Indibulin (an orally applicable inhibitor of tubulin assembly), linked via the ADC linker MC-Val-Cit-PAB.
    MC-Val-Cit-PAB-Indibulin
  • HY-131089
    MC-VC-PABC-C6-α-Amanitin
    		98.88%
    MC-VC-PABC-C6-α-Amanitin is an antibody agent conjugate consisting of an anticancer toxin alpha-Amanitin (HY-19610) and a monoclonal antibody MC-VC-PABC-C6. Among them, alpha-Amanitin is a potent inhibitor of RNA polymerase IIα. MC-VC-PABC-C6-α-Amanitin accurately targets HER2 receptors, specifically recognizes HER2-positive tumor cells. It is widely used in breast cancer and gastric cancer research.
    MC-VC-PABC-C6-α-Amanitin
  • HY-145989S
    Aminobenzenesulfonic auristatin E-d8
    		98.02%
    Aminobenzenesulfonic auristatin E-d8 is the deuterium labeled Aminobenzenesulfonic auristatin E. Aminobenzenesulfonic auristatin E is a drug-linker conjugate for ADC. Aminobenzenesulfonic auristatin E has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic[1][2].
    Aminobenzenesulfonic auristatin E-d<sub>8</sub>
Drug-Linker Conjugates for ADC Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.